Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Slides:

Advertisements

Similar presentations

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Five-year clinical follow-up of unprotected left main bifurcation lesion.

Advertisements

INTRAVASCULAR ULTRASOUND EVALUATION OF COMPLEX BIFURCATION LESIONS TREATED WITH TRYTON SIDE-BRANCH STENT IN CONJUNCTION WITH EVEROLIMUS-ELUTING STENTS.

Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.

J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.

Complex Coronary Cases

A multicenter, randomized, prospective DKCRUSH-III study

Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent.

BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.

Bifurcation Overview A comprehensive overview of Bifurcation disease, treatment options and techniques.

Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.

BIFURCATION LESIONS Dr. Tahsin.N

Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)

Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy Presented by Jay Yadav, MD on behalf of the SAPPHIRE Investigators.

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

Stenting with or without Protection in High-Risk Patients with Moderate to High-Grade Carotid Stenosis Presented at ACC 2003 Late Breaking Clinical Trials.

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.

BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.

British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.

Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.

Direct Stenting is Better (Debate Session) 동아의대 김 무 현.

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

Lianglong Chen MD PhD FACC

“Randomized Comparison between Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs. Paclitaxel (Taxus vs.Costar) Eluting Stents in Coronary Lesions:

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.

Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

Will we ever see a dedicated bifurcated DES in clinical practice?

Bifurcation PCI: Basic Techniques and Data from Clinical Trials

Strategy planning in coronary bifurcation stenting

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Study Design AMI <12 hours, any age, cardiogenic shock excluded

Stenting of Coronary Arteries in Non Stress/Benestent Disease

TAXUS II and IV: two-year follow-up

SKS Technique Clinical Case

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

Primary endpoint at 1 year

FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.

REALITY: 8 month results

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

Presented at ACC 2003 Late Breaking Clinical Trials

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

Bifurcation Disease: Simulation Training Curriculum

Main branch restenosis at 1 year

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Fadi J. Sawaya et al. JCIN 2016;9:

Fadi J. Sawaya et al. JCIN 2016;9:

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Presented at TCT 2006.

MACE: Death, MI or TLR at 5 years

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Presentation transcript:

www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl PTCA of sidebranch with final kiss n=206 n=206 Cypher of side branch with final kiss (“crush”, “culotte”, “Y”, or other technique) n=207 Cypher of side branch with final kiss (“crush”, “culotte”, “Y”, or other technique) n= patients at 28 centers in 5 countries with true bifurcation lesions received Cypher stents in the main vessel Randomized. Clinical follow-up at 6 months 413 patients at 28 centers in 5 countries with true bifurcation lesions received Cypher stents in the main vessel Randomized. Clinical follow-up at 6 months The Randomized Nordic Bifurcation Trial Steigen TC et al. ACC 2006

www. Clinical trial results.org Nordic Bifurcation Trial: Methods and Results PTCACypher (“crush”, “culotte”, “Y”, or other technique) n=206n=207 MV stented (%) NS SB stented (%) <0.001 Kissing balloon (%) 3274<0.001 Tx successful (%) 9795NS Presented at TCT 2006 Steigen TC et al. ACC 2006

www. Clinical trial results.org Nordic Bifurcation Study Major Endpoints Primary Endpoint Presented at TCT 2006 In-hospital MI (%) p=0.30 CKMB >3x nl 6 month MACE (%) p=0.01 Steigen TC et al. ACC 2006